1. Mavacamten demonstrated substantial enhancement in alleviating valsalva left ventricular outflow tract (LVOT) obstruction in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) compared to placebo, with favorable tolerability. 2. Additionally, all secondary measures of effectiveness, including New York Heart Association (NYHA) functional class, health status, cardiac biomarkers, and cardiac structure, displayed improvements. Evidence Rating
Spotlight Interview: James Passafaro, Chef and Cofounder, opsi restauranttechnologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from restauranttechnologynews.com Daily Mail and Mail on Sunday newspapers.
MENA Solar Conference to focus on six innovative research areas zawya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zawya.com Daily Mail and Mail on Sunday newspapers.